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ABSTRACT
Lamin A is a component of the nuclear matrix that also controls proliferation by 
largely unknown mechanisms. NF-Y is a ubiquitous protein involved in cell proliferation 
composed of three subunits (-YA -YB -YC) all required for the DNA binding and 
transactivation activity. To get clues on new NF-Y partner(s) we performed a mass 
spectrometry screening of proteins that co-precipitate with the regulatory subunit 
of the complex, NF-YA. By this screening we identified lamin A as a novel putative 
NF-Y interactor. Co-immunoprecipitation experiments and confocal analysis confirmed 
the interaction between the two endogenous proteins. Interestingly, this association 
occurs on euchromatin regions, too. ChIP experiments demonstrate lamin A 
enrichment in several promoter regions of cell cycle related genes in a NF-Y dependent 
manner. Gain and loss of function experiments reveal that lamin A counteracts NF-Y 
transcriptional activity. Taking advantage of a recently generated transgenic reporter 
mouse, called MITO-Luc, in which an NF-Y–dependent promoter controls luciferase 
expression, we demonstrate that lamin A counteracts NF-Y transcriptional activity 
not only in culture cells but also in living animals. Altogether, our data demonstrate 
the occurrence of lamin A/NF-Y interaction and suggest a possible role of this protein 
complex in regulation of NF-Y function in cell proliferation.
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INTRODUCTION
NF-Y is an heterotrimeric transcriptional factor 
composed of 3 proteins, the regulatory subunit NF-YA, 
NF-YB and NF-YC. The three proteins are transcribed 
from independent genes highly conserved from yeast to 
human. All 3 proteins are necessary for NF-Y binding to 
the target DNA sequence, the CCAAT-box. The NF-YA 
subunit contain a DNA binding domain, an activation 
domain and the binding site for the dimer NF-YB/-YC. The 
NF-YB and -YC subunits contain histone-like domains 
[1]. A bioinformatic analysis of promoters of cell-cycle 
regulatory genes demonstrated that CCAAT box is one of 
the most represented cis-regulatory elements in particular 
on promoters regulated during the G2/M transition [2]. In 
agreement, growing number of experiments demonstrate 
that the NF-Y complex is a key regulator of cell-cycle 
genes responsible for cell progression in all cell cycle 
phases among which are mitotic cyclin complexes [3–10]. 
Taken together, these studies demonstrate that NF-Y is a 
major player in the regulation of proliferation.
It has been reported the presence of two major NF-
YA isoforms, “long” and “short”, the short isoform lacking 
a 28-amino acid within the NF-YA amino-terminal domain 
[11]. Expression of NF-YA subunit is tightly regulated 
in normal cells during the cell cycle [4], moreover, in 
agreement with the key role of NF-Y on proliferation, the 
abrogation of expression of its regulatory subunit NF-YA 
plays an important role in downregulating cell-cycle genes 
in differentiated cells [5, 7–10]. Previous studies have used 
a loss of function approach in order to study the biological 
role of NF-Y. The overexpression of a NF-Y dominant 
negative protein in mouse fibroblasts leads to a retardation 
of cell growth [12]. The knock out of the NF-YA subunit 
in mice leads to embryo lethality; moreover, knock out 
of the NF-YA gene in mouse embryonic fibroblasts leads 
to a cell cycle arrest with a consequent inhibition of cell 
proliferation [13–14]. Abundant evidences indicate that 
NF-Y plays a role in carcinogenesis. We have demonstrated 
that NF-Y regulates transcription of several genes upon 
DNA damage [15, 16], and NF-Y overexpression increased 
cell proliferation in cell expressing endogenous mutant 
p53. Next, we have described an in vivo NF-Y/mutant p53 
complex able to increases DNA synthesis, in a NF-YA 
dependent manner [8, 17]. Clinical studies have revealed 
that increased expression of NF-Y target genes correlates 
with poor prognosis in multiple cancers [8, 18]. Analysis 
of transcriptome profiles across human cancers revealed 
the involvement of NF-Y in cancer-associated pathways 
[19]. In agreement with its wide involvement on human 
cancers, we have described that NF-Y interacts with 
different partners. Indeed, we have shown that in normal 
cells NF-YA binds to deacetylase enzymes (HDACs) while 
in transformed cells the acetylase p300 is preferentially 
recruited [8–9]. Although some NF-Y interactors are 
already known, several partners through which NF-Y 
exerts its role still need to be characterized.
The major components of the nuclear lamina are 
lamins. These type V intermediate filament (IF) proteins play 
important roles in nuclear architecture, mechanosignaling 
[20] and chromatin dynamics [21], and impact on stem cell 
proliferation and differentiation [22, 23]. Disruption of one 
or more of these functions due to lamin mutations cause 
a group of inherited diseases affecting various tissues and 
organs or causing accelerated ageing [24]. In mammal exist 
four lamins isoforms: A-type lamins, counting lamin A and 
lamin C, and B type lamins, including B1 and B2. Lamin A 
and lamin C, encoded by LMNA gene, are expressed only in 
differentiated cells, while Lamin B1 and lamin B2, encoded 
by LMNAB1 and LMNAB2 genes, are expressed throughout 
development. Prelamin A (the precursor of lamin A protein) 
and lamin C are produced by an alternative splicing within 
exon 10. The two proteins differ in the carboxyterminal 
domain where the human lamin A (646aa) contains 80 
unique amino acids and lamin C (572aa) contains 6 unique 
amino acids. It has been shown that lamin A/C stabilizes the 
nuclear lamina and chromatin, preventing DNA breaks and 
favouring epigenetic stabilization.
The nuclear lamina interacts with large genomic 
regions, called lamina-associated domains (LADs). LADs 
are often located in repressive chromatin structures that 
appear principally at the nuclear periphery [25, 26]. Besides 
the well characterized localization at nuclear membranes, 
lamins display also a nucleoplasmic localization with 
distinct roles [27–30]. It has been demonstrated that the 
two isoforms, lamin A and C, participate, at least in part, to 
distinct networks in the nuclear lamina [31].
Lamins A and C are implicated in epigenetics, 
heterochromatin organization and are shown to complex 
with histones and key regulator of transcription such as 
pRB (retinoblastoma-associated protein), MOK2 (zinc 
finger transcription repressor), several components of 
the Pol II (RNA polymerase II) complex [32]. Lund et 
al have already demonstrated that lamin A and C can 
associate with euchromatic regions [33, 34]. Lamin A 
expression is downregulated or absent in cells that are 
highly proliferative, including various human malignancy 
[35]. Loss of lamin A expression has been reported for 
colon cancer, cervical cancer, lung cancer, prostate 
cancer, gastric cancer, ovarian cancer and leukemia and 
lymphoma [35–39]. Moreover, the lamin A knock down 
increase the proliferative potential of cells and impairs 
cell cycle arrest induced by contact inhibition [40]. Recent 
data highlight the specific functions of a small pool of 
lamina-independent A-type lamins, located throughout the 
nucleoplasm, in the regulation of early tissue progenitor, 
cell proliferation and commitment [41, 42].
Using a combination of biochemical, cell biology 
and molecular imaging techniques, we demonstrate here 
that NF-Y, a master regulator of cell proliferation, forms 
a complex with a component of the nuclear lamina, lamin 
A. This interaction impacts on the expression of NF-Y 
target cell cycle regulatory genes and consequently cell 
proliferation.
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RESULTS
NF-Y interacts in vivo with lamin A
To get clues on NF-Y function(s) in cancer cells, 
we performed a mass spectrometry screening of a pool 
of proteins that co-precipitate with the long NF-YA 
isoform overexpressed in human breast cancer, SKBR3 
cells. By this screening we identified lamin A, but not 
lamin C, as a novel putative NF-YA interactor (Figure 1A, 
supplementary Table S1).
Figure 1: Analysis of the occurrence of lamin A/NF-Y complex in several cell lines. A. Lamin A interacts with NF-YA. Silver-
stained SDS-PAGE gel of the immunoprecipitates with the indicated antibodies from SKBR3 cells. Arrow indicates proteins identified 
by mass spectrometry specifically associated to NF-YA. ctr cell extract, cellular extracts incubated with protein G-Sepharose without 
antibody; ctr ab, anti-NF-YA polyclonal antibody-protein-G complexes without cellular extracts B. Whole cell lysates from several cell 
lines were analyzed by western blotting with anti-NF-YA and lamin A antibodies. C. Whole cell lysates from several cell lines were 
immunoprecipitated with an antibody against NF-YA, and western blotting was performed with antibodies to lamin A and NF-YA. D. Whole 
cell lysates from several cell lines were immunoprecipitated with an antibody against lamin A/C, and western blotting was performed with 
an antibody anti lamin A/C, NF-YA (monoclonal) and NF-YB. As a reference, 1/20 of whole cell extract used in the immunoprecipitations 
was loaded (input). As negative control, in (C) and (D) were used SW480 cell lysates immunoprecipitated with an anti-IgG antibody. E. 
Immunoprecipitation experiments were performed with whole cell lysates produced from SW480 cells transiently transfected with NF-YA 
(NF-YA) or a dominant negative mutant of NF-YA subunit (dnNF-YA), or with the empty vector (mock), using antibodies against LaminA. 
In panel B, C, D, E Long 40 kD means long isoform of NF-YA subunit and Short 37 kD short isoform of NF-YA subunit. F. Confocal 
analysis performed on proliferating SW480 cells using antibodies against NF-YA (tritc) and lamin A (fitc). Different optical fields are 
shown. Colocalization (yellow) of endogenous NF-YA (red) and lamin A (green) was analyzed by indirect immunofluorescence combined 
with Confocal Scanning Laser Microscopy. Confocal analysis of single optical section is shown. Different optical fields are shown. G. 
Confocal analysis on mitotic SW480 cells using antibodies against NF-YA (tritc) and lamin A (fitc). Colocalization (yellow) of endogenous 
NF-YA (red) and lamin A (green) was analyzed by indirect immunofluorescence combined with Confocal Scanning Laser Microscopy. The 
images have been collected with a 60x oil objective. (Long 40kD) long isoform of NF-YA subunit; (Short 370kD) short isoform of NF-YA 
subunit.
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The occurrence of laminA/NF-Y interaction was 
also validated by coimmunoprecipitation experiments 
between endogenous proteins. As already described it 
has been reported the presence of two NF-YA isoforms, 
“long” and “short”. As shown in Figure 1B, both lamin 
A and the two NF-YA isoforms are expressed in all 
tested cell lines. Lysates from these growing cells were 
immunoprecipitated with an antibody against NF-YA and 
subjected to western blot analysis. Endogenous lamin 
A, but not lamin C, coimmunoprecipitated with both 
differentially spliced forms of endogenous NF-YA protein 
in all cell culture lines (Figure 1C).
Reciprocal immunoprecipitation experiments 
performed with anti-lamin A/C antibody further validated 
the occurrence of endogenous lamin A/NF-YA in all tested 
cell lines (Figure 1D). Apparently, lamin A differently 
immunoprecipitates the two isoforms depending on 
cell lines. However, using in WB a different antibody 
against NF-YA we observed a more similar lamin A 
immunoprecipitated NF-YA pattern (Supplementary Figure 
1A) clearly indicating that the difference observed in Figure 
1D could be due to the anti- NF-YA antibody used in WB. 
As expected NF-YB subunit is present in the complex, too. 
As shown in Figure 1D and in Supplementary Figure 1B, 
an antibody against NF-YB protein immunoprecipitated 
lamin A, further confirming the involvement of this subunit 
in the complex and thus indicating that lamin A associates 
with the NF-Y complex and not with the NF-YA subunit 
alone. Transfection with plasmid encoding the long form of 
NF-YA in SW-480 cells confirmed this result (Figure 1E). 
We also overexpressed the dominant negative mutant of 
NF-YA subunit (dnNF-YA) that carrying a triple aminoacid 
substitution in the DNA binding domain does not bind 
DNA and impairs NF-YA transcriptional activity [43]. 
Results demonstrate that dnNF-YA mutant form is still able 
to efficiently bind lamin A thus suggesting that the DNA 
binding domain of NF-YA is not necessary for its interaction 
with lamin A (Figure 1E).
To demonstrate the specificity of lamin A/NF-YA 
interaction we evaluated the interaction of lamin A with 
p53, a well known NF-Y interactor. The results presented 
in supplementary Figure 1C demonstrate that lamin A 
does not interact with p53, thus confirming the interaction 
specificity between lamin A and NF-YA. As expected, NF-
YA immunoprecipitates p53 [8]. These results indicate 
the specificity of the association of lamin A with NF-YA 
under our experimental conditions and suggest that p53 
may be not involved in the formation of the laminA/
NF-Y complex. Confocal analysis results obtained on 
several proliferating cells are compatible with lamin A/
NF-YA interaction both in interphase (Figure 1F and 
Supplementary Figure 1D) and in different mitosis phases 
(Figure 1G). Interestingly, we observed a colocalization 
of lamin A and NF-YA both in the nucleoplasm and in 
the nuclear lamina. Taken together, our data reveals the 
occurrence of a lamin A/NF-Y nuclear complex.
NF-YA localizes in lamin enriched nuclear 
fractions
To study the function of a complex often is critical 
the identification of cellular compartment (s) where the 
interaction between the two proteins occurs. To get clues 
on lamin A and NF-YA physical interaction, we isolated 
different lamin enriched nuclear fractions (Supplementary 
Figure 2A). We isolated nuclei in hypotonic buffer. Firstly, 
we verified the presence of lamin A by western blot on 
resuspended nuclei (Supplementary Figure 2B). We treated 
isolated nuclei with moderate-salt buffer to solubilize most 
nuclear proteins, and then pelleting to obtain a lamin-
enriched pellet. The lamin-enriched pellet was solubilized 
by high pH and high detergent and, upon centrifugation, 
we separated soluble lamins from insoluble pellet [44]. The 
two fractions were studied for the presence of lamin A and 
NF-YA. As expected, both lamin A and C were present on 
soluble lamin-enriched fractions and they are still present 
on insoluble pellet. Interestingly, NF-YA was found both 
in the lamin-enriched fractions and on insoluble pellet thus 
suggesting NF-YA as a nucleoskeletal protein (Figure 2A).
Recent data support a role for lamin A in gene 
regulation through its interaction with chromatin [45]. 
Thus we asked whether the interaction of lamin A and NF-
YA occurs on chromatin. To this purpose, we generated 
chromatin and nucleoplasm fractions from different cell 
lines. We isolated nuclei in isotonic-sucrose based buffer and 
we separated nucleoplasm and chromatin (Supplementary 
Figure 3A). As shown in Figure 2B, both NF-YA and lamin A 
were found in the chromatin fraction. NF-YA was present in 
nucleoplasm deprived of chromatin while lamin A was almost 
undetectable in this fraction. Next, we performed reciprocal 
co-immunoprecipitation experiments using chromatin 
fractions from several cell lines. The antibody against NF-YA 
immunoprecipitates lamin A and viceversa in all tested cell 
lines (Figure 2C). Again, with this experiment we confirmed 
NF-YA binding with lamin A, but not with lamin C. All 
together these results strongly reinforce the thesis that lamin 
A/NF-YA association occurs on chromatin, too.
Lamin A is enriched in promoter regions 
encompassing CCAAT boxes
To start to investigate whether lamin A localizes on 
euchromatin, where NF-Y plays a key role as transcription 
factor, we first isolated euchromatin fraction from several 
cell lines (Supplementary Figure 3A). To this purpose, we 
subjected the above isolated chromatin to mild MNase 
digestion to separate euchromatin, more accessible to 
MNase digestion. A time course for MNase digestion up to 
30 minutes was performed on chromatin from SW-480 and 
MCF-7 cells in order to determine the minimal incubation 
time necessary for NF-YA extraction in the euchromatin 
fraction. After 5 minutes NF-YA and lamin A were both 
detected in the supernatant (Supplementary Figure 3B).
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Based on this result, we digested for 5 minutes 
chromatin from several cell lines and analyzed it by agarose 
gel (Supplementary Figure 3C). In all employed cell lines we 
observed an enrichment of mono-, di- and tri-nucleosomes 
thus indicating an enrichment of euchromatin in these 
fractions. Interestingly, by western blot we demonstrated 
that NF-YA and lamin A are present in this fraction in all 
tested cell lines (Figure 2D and Supplementary Figure 3D). 
Taken together the results obtained so far demonstrate the 
occurrence of a lamin A/NF-Y interaction on chromatin 
and the two proteins localize on the same open chromatin 
fraction thus suggesting the possibility that they cooperate 
on gene regulation.
To address this hypothesis we performed ChIP 
experiments followed by quantitative real time PCR 
(ChIP-qPCR). Specific primers were used to amplify DNA 
Figure 2: NF-Y localizes in lamin-enriched nuclear fraction and associates with lamin A in the chromatin fraction. A. 
Western blotting of soluble (1) and insoluble (2) lamin enriched fractions obtained following the procedure described in Supplementary 
Figure 2A from SW480 and MCF7 cell lines using anti-NF-YA or -LaminA antibodies. B. Chromatin and nucleoplasm fractions obtained 
following the procedure described in Supplementary Figure 3A from SW480 and MCF7 cell lines were subjected to western blotting 
analysis using anti-NF-YA or -LaminA antibodies. β actin was used as loading control. C. Immunoprecipitation experiments using chromatin 
fraction isolated from MCF7, SW480 and SKBR3 cell lines obtained following the procedure described in Supplementary Figure 3A using 
anti-NF-YA and lamin A antibodies followed by western blotting analysis using antibodies against the indicated proteins. D. Euchromatin 
fractions were produced by digestion of chromatin with Micrococcal nuclease as described in Supplementary Figure 3. These fractions were 
loaded onto a SDS polyacrylamide gel and analyzed by western blotting using the antibodies against the indicated proteins.
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regions encompassing NF-Y consensus sites on several 
NF-Y target promoters. Our experiments performed with 
two different antibodies against lamin A, demonstrate that 
it associates, although at different extent, with several 
promoter regions carrying the CCAAT-boxes, such as 
CCNB2, DHFR, CCNA2, CDK1, CCNB1, CDC25C, 
TOPO2A and PCNA promoters (Figure 3A). As expected 
[9], NF-Y binds all these promoter regions (Figure 3B). In 
contrast, when using primers corresponding to sequence 
of an unrelated promoter (CXCR4 promoter) that does not 
Figure 3: ChIP-qPCR analysis on CCNB2, DHFR, CCNA2, CDK1, CDC25C, TOPO2A, and PCNA promoters with 
anti-lamin A/C and lamin A antibodies A. and anti-NF-YA antibody B. using mock transfected (ctr) and a dominant 
negative NF-Y (dnNF-YA) transfected SW480 cells. C. ChIP-qPCR analysis, on SW-480 cells, of CXCR4 promoter that does not 
contain CCAAT boxes used as unrelated promoter with anti-LMNA/C, LMNA and anti-NF-A antibodies. D. ChIP–qPCR analysis, with 
anti-LaminA/C antibody, of a telomeric region (ITS18-1), a DNA region immediately adjacent to the telomere (Tel-Adj), and a DNA region 
without an ITS (RPLP0). In all experiments, the ChIP-qPCR results obtained by 3 independent replicate experiments are represented as 
percentage of input (% Input) on a logarithmic scale, the error bars indicate the standard error. No antibody values were subtracted. The 
error bars indicate the standard error.
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contain CCAAT boxes, we did not find any specific lamin 
A in vivo recruitment (Figure 3C). Moreover, we validated 
the specificity of anti- lamin A/C antibody used in ChIP-
qPCR. It has already been demonstrated that lamin A/C 
specifically associates with sequences named interstitial 
telomeric sequences (ITSs) [46]. Indeed, we performed 
ChIP–qPCR analysis in SW-480 cells of a telomeric 
sequence (ITS18-1), of a sequence in close proximity 
of the telomere (Tel-Adj), and of a site without an ITS 
(RPLP0). As shown in Figure 3D, our data confirmed the 
specificity of lamin A/C enrichment at the ITS region, 
whereas the association was not observed at the Tel-Adj 
site and at the RPLP0 site.
To directly assess the role of NF-Y in the recruitment 
of lamin A to the NF-Y target promoter regions carrying 
CCAAT boxes, we performed ChIP experiments upon 
overexpression of dnNF-YA mutant protein in SW480 
cells. ChIP-qPCR analysis shows that the overexpression 
of dnNF-YA induces a decreased recruitment of NF-Y 
(Figure 3B), and this correlates with a reduction of lamin 
A binding in five of the eight promoter regions analyzed, 
such as CCNB2, DHFR, CDC25C, TOPO2A and PCNA, 
(Figure 3A), although at different extent depending on the 
analyzed promoter. These data suggest that the binding of 
lamin A to some promoter regions carrying CCAAT-boxes 
may be dependent on the binding of NF-Y complex.
Very recently, it has been demonstrated that lamin 
A/C is able to bind to specific DNA sequences [47]. 
We investigated the presence of these sequences in 
the promoter regions analyzed (Supplementary Figure 
4A). We found some of them in the close proximity of 
the CCAAT boxes but, very interestingly, they were 
particularly enriched in CDK1, CCNA2 and CCNB1 
promoters that did not show any modulation of lamin 
A/C recruitment after dnNF-YA overexpression, thus 
suggesting that lamin A/C may interact through its direct 
DNA binding in these promoter regions.
Taken together, our data demonstrate that the 
binding of lamin A to CCAAT containing promoter 
regions of several cell cycle genes is largely dependent 
on the binding of NF-Y complex, and indicate that lamin 
A binds these promoters through its ability to bind NF-Y.
Lamin A impacts on NF-Y transcriptional 
activity
To characterize the functional role of the lamin 
A binding to NF-Y target promoters, we investigated 
the chromatin structure of the promoter regions bound 
by lamin A/C and NF-Y. We performed ChIP-qPCR 
experiments using antibodies against H4K20me3 and 
H3K14ac, hallmarks of closed and open chromatin 
structure, respectively. Previous analysis demonstrated an 
excellent correlation between NF-Y binding and regions 
enriched for histone modifications associated with active 
transcription [9]. As expected, we observed an enrichment 
of H3K14ac on these regions thus demonstrating their 
open chromatin configuration and transcription-permissive 
state (Figure 4A).
Thus, we asked whether the depletion of lamin 
A affects histone modifications and we compared the 
recruitment of H3K14ac on several NF-Y target promoter 
regions in cells silenced for lamin A. On this purpose, 
we produced stable siLMNA SW-480 and SAOS-2 cells 
(LMNA-KD cells) showing a reduction in the protein level 
of lamin A of about 60% and 70%, respectively, compared 
to control cells transfected with the same vector carrying 
a non-targeting artificial siEmGFP-miRNA (Figure 4B). 
Results shown in Figure 4C demonstrate an increase 
of H3K14ac binding in LMNA KD cells, suggesting a 
specific role of lamin A on regulation of cell cycle gene 
promoters target of NF-Y activity.
Next, to investigate the transcriptional activity 
of these promoter regions we performed ChIP-qPCR 
experiments using antibodies against RNA polymerase 
II active isoforms. Of note, the transcriptionally active 
phosphorylated forms of RNA Polymerase II (Ser-2 and 
Ser-5) are recruited to all the analyzed regions, thus further 
indicating gene activation (Figure 4D). The same results 
were obtained by ChIP followed by semiquantitavie 
PCR, amplifying CCNB2 promoter as prototype of NF-Y 
target gene (Supplementary Figure 4B, 4C). Altogether, 
the results clearly demonstrate that lamin A may interact 
with NF-YA on chromatin of NF-Y target genes in an open 
conformation status and actively transcribed.
We confirmed the involvement of lamin A on NF-Y 
target gene transcription using CCNB2 promoter driven 
luciferase reporter construct as a sensor of NF-Y activity. 
We transiently overexpressed this construct in SW-480 
cells together with a vector expressing NF-YA and/or 
a vector that allows the simultaneous expression of an 
artificial miRNA able to target the mRNA of lamin A, and 
the EmGFP reporter gene as control (pcDNA6.2-GW/
EmGFP-miR-LMNA) [33]. Our data suggest that down-
modulation of lamin A, although not complete (Figure 4E), 
led to a significant increase of CCNB2 promoter activity 
upon NF-YA overexpression (Figure 4F) thus supporting 
the hypothesis that lamin A may interfere with NF-Y 
activity. To validate these data, we used LMNA-KD cells. 
We observed an increase of CCNB2 promoter activity 
in LMNA-KD cells (Figure 4G). We also employed a 
CCNB2 promoter construct carrying 3 mutated CCAAT 
boxes (mut cyclin B2 promoter). As already shown 
[4], the basal CCAAT-less promoter activity of the mut 
cyclin B2 promoter was significantly reduced compared 
to the wt construct but lamin A modulation did not affect 
significantly the residual activity (Figure 4G). Since lamin 
A knockdown increases cylin B2 promoter activity, we 
asked whether this activity go back down by inhibiting 
NF-Y activity. To answer this question we overexpressed 
cyclin B2 promoter driven luciferase reporter construct 
together with the vector expressing dnNF-YA protein in 
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Figure 4: Lamin A is involved in NF-Y transcriptional activity. A. ChIP-qPCR analysis performed on SW480 using anti-H3K4me3 
and H3K14ac antibodies using specific primers to amplify DNA regions encompassing NF-Y consensus sites on CCNB2, DHFR, CCNA2, 
CDK1, CDC25C, TOPO2A, and PCNA promoters. B. Western blotting of total cell lysates from SW-480 and SAOS-2 mock transfected 
(CTR) or LMNA-KD stable transfected cells (LMNA-KD) with lamin A/C antibody. Bands were quantified by densitometry using UVI-
1D quantification module. Histogram shows the quantitative densitometry of lamin A protein (fold over control) normalized over β actin 
expression, as mean S.E. from three independent experiments. C. ChIP-qPCR analysis performed on SW480 mock transfected (CTR) or 
LMNA-KD stable transfected cells (LMNA-KD), using anti-H3K14ac and specific primers to amplify DNA regions encompassing NF-Y 
consensus sites on CCNB2, DHFR, CCNA2, CDK1. D. ChIP-qPCR analysis performed on SW480 using anti-pol II phospho-ser 3 (Pol 
IIS2) and pol II phosphor-ser 5 (Pol IIS5) antibodies using specific primers to amplify DNA regions encompassing NF-Y consensus sites 
on CCNB2, DHFR, CCNA2, CDK1, CDC25C, TOPO2A, and PCNA promoters. The ChIP results obtained by 3 independent replicate 
experiments are represented as percentage of input (% Input) on a logarithmic scale, the error bars indicate the standard error. No antibody 
values were subtracted. In (A), (C) and (D) mean of 3 independent replicate experiments are represented as percentage of input (% Input) 
on a logarithmic scale, the error bars indicate the standard error. E. Western blotting showing the expression levels of lamin-A and NF-
YA proteins in SW480 cells transiently transfected with cyclin B2 promoter construct driven luciferase gene. Cells were transiently co-
transfected with the indicated vectors and used for luciferase assays. β actin was used as loading control. F. Luciferase assays performed in 
SW480 cells described above after 48 hrs post transfection. Promoter activity is expressed as fold change of firefly/Renilla luciferase ratio. 
Results were obtained by eight independent replicate experiments. G. Luciferase assays performed with LMNA knock-down in SW480 
cells (LMNA-KD), transfected with the CCNB2 luciferase construct carrying the wild type cyclinB2 promoter (wt cyclinB2 promoter) 
or cyclin B2 promoter mutated on the 3 CCAAT boxes (mut cyclinB2 promoter). Promoter activity is expressed as fold change of firefly/
Renilla luciferase ratio. Results were obtained by 10 independent replicate experiments. The error bars indicate the standard error. H. 
Luciferase assays performed in SW480 cells transfected with cyclin B2 promoter construct driven luciferase gene. Cells were transiently 
co-transfected with the indicated vectors and luciferase assays were performed after 48 hrs. Promoter activity is expressed as fold change of 
firefly/Renilla luciferase ratio (n=3). I. qPCR analysis of expression levels of the indicated mRNA in LMNA-KD versus mock transfected 
cells (ctr) (n=3). L. Western blotting analysis with the indicated antibodies of whole cell lysate (total lysates), cytosolic and nuclear extracts 
and euchromatin fraction with the indicated antibodies produced from mock transfected (CTR) or LMNA-KD stable transfected SW480 
cells. Statistical significance: *p<0.05. **p<0.01.
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LMNA-KD and control cells. As expected, dnNF-YA 
inhibits cyclin B2 promoter and, of note, it is able to rescue 
its activity upregulation observed in cells lacking lamin A 
(Figure 4H). These data indicate that lamin A depletion 
activates cyclin B2 promoter transcription through 
NFY activation. In agreement with the above results we 
observed in LMNA-KD cells an increase of the amount 
of several NF-Y target mRNAs such as CCNB2, DHFR, 
CCNB1, CDC25C and CDK1 (Figure 4I). As shown in 
Figure 4L, NF-Y localization on euchromatin was not 
affected by lamin A silencing. This result suggests that, 
very likely, the enhanced NF-Y transcriptional activity 
observed by lamin A silencing depends on a decreased 
number of lamin A molecules able to associate with NF-Y 
and inhibits its activity.
Next, we stably transduced in SW-480 cells a 
human lamin A (lamin A-res) expressing vector resistant 
to siRNAs [48] (Figure 5A). Lamin A resistant cDNA was 
designed to contain several silent codon changes at the 
target sites of the miRNAs, thereby rendering it resistant 
Figure 5: Lamin A inhibits NF-Y-dependent gene expression. A. Western blot performed with total lysate from mock or stably 
transfected SW480 cells with a human lamin A expression vector coding for a laminA resistant to siRNAs (lamin A-res). Bands were 
quantified by densitometry using UVI-1D quantification module. Histogram shows the quantitative densitometry of lamin A protein (fold 
over control) normalized over β actin expression, as mean S.E. from three independent experiments. B. Luciferase assays performed in 
lamin A-res SW480 cells versus mock cells (CTR) transfected with the CCNB2 promoter luciferase construct (wt cyclin B2 promoter) 
or cyclin B2 promoter carrying mutated CCAAT boxes (mut cyclin B2 promoter) (n=3). C. Expression levels by qPCR of the indicated 
mRNAs in lamin A-res SW480 cells (lamin A-res) versus mock cells (ctr) (n=3). In all experiments, the error bars indicate the standard 
error. Statistical significance: *p<0.05, **p<0.01.
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to the endogenous miRNAs. Consistent with our previous 
results, expression of lamin A-res led to a reduction of 
the basal CCNB2 promoter activity of approximately 
30% (Figure 5B) and to a decrease of CCNB2, DHFR, 
CCNB1, CDC25C and CDK1 mRNA levels (Figure 5C). 
Also in these cells, CCNB2 promoter construct carrying 
two mutated CCAAT boxes (mut CCNB2 promoter) was 
not affected by lamin A modulation (Figure 5B).
To demonstrate in vivo the impact of lamin A on 
NF-Y transcriptional activity we took advantage of the 
MITO-Luc mouse model, that we recently developed, 
carrying a luciferase reporter driven by a promoter 
strictly dependent on NF-Y allowing us to monitor 
the NF-Y activity within the entire living organism in 
a spatiotemporal manner [49]. We demonstrated that 
intravenous injection of a viral vector expressing dn-
YA in MITO-Luc mice an almost complete inhibition of 
luciferase activity is observed in every body area. Thus, 
we reasoned that it was possible to overexpress lamin A in 
our MITO-Luc mice by injecting the viral vector encoding 
lamin A-res described above [48]. We injected MITO-
Luc mice intravenous with lamin A-res viral vector and 
we followed luciferase activity in the entire animals for 
several days. We have previously described that in MITO-
Luc mice high luciferase activity is exerted in the bone 
marrow contained in the long bones and in the spleen [49]. 
Of note, lamin A-res injection results in an inhibition of 
luciferase activity emitted by these tissues at any tested 
time (Figure 6A). In these graphs the values coming from 
the pre injection imaging session are reported as 1 and 
the other values are relative to this value in each mouse. 
Representative images of a control and injected mouse 
are shown in Figure 6B. It is important to notice that 
the values are relative to the value of mouse is imagined 
Western blot analysis conducted on extracts from these 
tissues at 7 days after lamin A-res injection confirmed 
the overexpression of lamin A in these tissues (Figure 
6C). Taken together, our results demonstrate that lamin A 
impacts on NF-Y transcriptional activity in cell cultures 
and living animals.
To investigate the role of lamin A in cell cycle 
progression, we performed time course experiments and 
compared the ability of SW-480 and SW-480 LMNA-KD 
cells to grow in 0, 1% serum or after hydrogen peroxide 
treatment (200μM H2O2). The growth of SW-480 cells was 
partially reduced upon growth factor deprivation (Figure 
7A) or upon oxidative stress conditions (Figure 7B) 
compared with control cells, whereas the growth of SW-
480 LMNA-KD cells was always not impaired indicating 
that lamin A knockdown increases cell proliferation. We 
asked whether NFY inhibition would rescue lamin A 
knockdown phenotype on cell proliferation. To answer 
this question we overexpressed dnNFYA in LMNA-KD 
cells and we observed a decrease of cell proliferation 
(Figure 7C). This results, together with the higher basal 
CCNB2 promoter luciferase activity observed both 
under serum deprivation and oxidative stress conditions 
in LMNA-KD cells compared with control cells (Figure 
7D), suggests that the lamin A knockdown-mediated 
increase in cell proliferation is actually mediated by NFY 
activation. Altogether, our data demonstrate lamin A as a 
novel repressor of NF-Y activity and indicate its role as a 
suppressor of cell proliferation. Moreover, we hypothesize 
a role of lamin A as a sensor of cellular stress, such as 
serum deprivation and oxidative stress.
DISCUSSION
In the present study, starting with a mass-
spectrometry screening, we identified a novel nuclear 
protein complex formed by lamin A and NF-Y involved in 
chromatin binding and cell proliferation.
NF-Y is a transcription factor able to binds the 
common CCAAT element and is generally considered a 
modulator of genes involved in growth promotion such 
as cell cycle regulatory genes [7, 9]. Numerous findings 
highlight that NF-Y has a role in cancer. Although 
mutations in NF-Y subunits have never been specifically 
identified in tumours, analysis of global regulatory 
perturbations across human cancers pointed at NF-Y as 
one of the transcription factors responsible for oncogenic 
transcriptional changes [19]. Thus, identification of NF-Y 
protein partners can help to characterize the mechanism 
associated with its tumorigenic potential.
Here, we demonstrated that lamin A associates with 
NF-Y, whereas lamin C is not present in the complex. This 
result is in accordance with a previous study reporting 
that lamin A and C are found, at least in part, in different 
complex within the lamina [31] and thus may participate 
to different protein complexes. We also provide evidences 
that lamin A interaction may affects NF-Y binding activity 
on promoter regions encompassing CCAAT boxes of 
NF-Y target genes modulating its transcriptional activity.
Although there are some evidences that lamin A 
binds DNA, directly or through the histone proteins, 
the role of nucleoplasmic lamin A is not completely 
understood, so far [35, 50]. Thus, we focused our 
study on the occurrence of lamin A/NF-Y association 
in the nucleoplasm compartment and, in particular, on 
chromatin where NF-Y exerts its role as transcription 
factor. In our study, we detected lamin A enrichment in 
promoter regions encompassing CCAAT boxes of several 
NF-Y target genes. These genes are actively transcribed 
as demonstrated by histone methylation marks and pol 
II recruitment. Interestingly, we observed that lamin A 
recruitment depended on NF-Y binding activity in five 
of the eight promoter regions analysed, such as CCNB2, 
DHFR, CDC25C, TOPO2A and PCNA, and at different 
extent, thus indicating that lamin A may specifically 
modulate NF-Y regulated promoter regions not only 
through interaction with NF-Y, but also via other proteins 
or through direct DNA binding, according with recent 
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evidences described in a recent paper indicating that lamin 
A/C directly binds to specific motifs in DNA segments 
[47].
Lamin A has been described to have a negative 
role on transcription. We clearly demonstrate that lamin 
A inhibits NF-Y transcriptional activity. These results 
suggest, therefore, that lamin-promoter interactions, per 
se, do not have a causative role on gene repression but may 
be able to modulate transcription in a manner dependent 
on local chromatin marks.
Numerous studies showed that lamin A can 
modulate gene expression through different mechanisms, 
among which the modulation of transcription factor 
subnuclear localization, the sequestering of transcription 
factors in inactive complexes, the regulation of their 
degradation [47, 51–55]. Interestingly, we observed that 
the NF-Y target CCNB2 promoter activity inversely 
correlated to lamin A expression and NF-Y transcriptional 
activity increases in lamin A silenced cells. Of note NF-Y 
localization on euchromatin was not affected by lamin A 
Figure 6: Lamin A impact on NF-Y activity in vivo. A. Quantification of emitted photon emission from femurs and spleen of MITO-
Luc mice was determined before infection (pre), 2, 4, and 7 days after injection (2gg, 4gg, 7gg). The retroviruses pMXIH-V5 (CRT), and 
pMXIH-human lamin A-res (LMNA) were used for infections. Bioluminescence was expressed as relative p/s/cm2/sr. B. Bioluminescence 
imaging of a representative MITO-Luc mouse before (Pre), after 2, 4, and 7 days (2gg, 4gg and 7gg) after infection. The area used for the 
photon emission quantification in (A) are indicated (femurs and spleen). The experiments were performed in eight animals. C. Western 
blotting analyses performed with total extract from bone marrow (BM) from long bones and spleen of mice after 7 days post-infection. 
Densitometry was performed with the ImageJ software (National Institutes of Health), values were normalized to actin and folds quantified 
with respect to untreated organs (CTR) set to 1.0.
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silencing (Figure 4F). This result suggests that, very likely, 
the enhanced NF-Y transcriptional activity observed in 
lamin A silenced cells depends on a decreased number 
of lamin A molecules able to associate with NF-Y and 
inhibit its activity. These results are coherent with previous 
evidences demonstrating thatdown-regulation of lamin 
A/C leads to dissociation of lamin A/C from promoters 
by enhancing transcriptional permissiveness [53]. It has 
been observed that lamin A interactions often appear to 
be confined to promoter subregions rather than to entire 
promoter regions. Our data support a view in which 
lamin A, through its ability to bind NF-Y, exerts a locus-
specific interaction with promoters important for cell cycle 
regulation and tumor progression.
Figure 7: Lamin A knock-down impacts on cell proliferation through NF-Y activity. SW480 mock transfected cells (ctr) and 
SW480 lamin A knock-down (LMNA-KD) cells were grown in 10% serum, 0, 1% serum or in 200 μM hydrogen peroxide (H2O2), viable 
cell number were counted daily. A. The growth of SW480 cells was partially reduced upon growth factor deprivation or B. upon oxidative 
stress conditions compared with control cells while the growth of SW480 LMNA-KD cells was not impaired. C. dnNF-YA expression 
rescue lamin A knock-down-mediate increase in cell proliferation in cells cultured in 0, 1% serum. D. Luciferase assays performed in 
SW480 LMNA knock-down (LMNA-KD) and in mock transfected cells (ctr) transiently transfected with the cyclinB2 luciferase promoter 
construct. Luciferase activity was normalized by Renilla luciferase, and means of 3 experiments performed in triplicates is presented as fold 
induction where luciferase in ctr cells is = 1. In all experiments, the error bars indicate the standard error. Statistical significance: *p<0.05, 
**p<0.01, ***<p< 0,001.
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In our study, an inverse correlation between lamin 
A and several NF-Y target genes expression level was 
observed, thus supporting the role of lamin A as regulator 
of NF-Y transcriptional function. We validated these 
evidences by in vivo imaging involving the use of a 
genetically engineered mouse model called MITO-Luc 
(for mitosis-luciferase), in which an NF-Y–dependent 
promoter drives luciferase expression. Data obtained 
strongly support the physiological impact of lamin A 
expression in cell proliferation.
NF-Y is one of the transcription factors responsible 
for aberrant oncogenic transcription occurring in several 
cancers [19]. Loss of lamin A expression has been 
reported in several cancers, and has been correlated with 
a more aggressive tumorigenic phenotype [56–60]. It is 
worth to note that cancer cells from solid tumors become 
metabolically stressed, when nutrients are insufficient 
within poorly vascularized regions. Metabolic stress 
results from severe deprivation of oxygen, glutamine and 
glucose, partly through excessive reactive oxygen species 
(ROS) production. Oxygen radicals may enhance cell 
migration rates and consequently increase tumor invasion 
and metastasis. Interestingly, our data obtained treating 
cancer cells under low nutrient and oxidative stress 
conditions indicate that loss of lamin A in cancer cells is 
associated with an increase NF-Y translational activity and 
with an increase of cellular proliferation ability compared 
with control cells. These data suggest that changes in 
lamin A expression could modulate NF-Y activity and, 
in particular, lamin A lost may correlate with an increase 
NF-Y oncogenic transcriptional potential.
Further exploration to uncover the molecular 
mechanism(s) by which NF-Y/ lamin A complex acts 
as crucial regulator in diverse cellular processes and, 
in particular, in cancer could be important to improve 
and potentially provide new clues into new therapeutic 
approaches for cancer treatment.
MATERIALS AND METHODS
Immunoprecipitation assay and mass 
spectrometry
Lysates (2 mg/sample) were precleared with 
Protein-G Agarose (Pierce) and incubated 4h at 4°C with 
an anti-NF-YA polyclonal antibody-protein-G complexes 
(50ul proteinG + 5ug antibody/sample) previously 
crosslinked by DMP (Sigma). We used two negative 
controls : 50ul of anti-NF-YA polyclonal antibody-
protein-G complexes immunoprecipitated without extract 
(ctr ab), 2 mg of cell extract immunoprecipitated with 50ul 
of protein-G without the antibody (ctr cell extract).
Immunoprecipitated proteins were resolved on a 
12%T- 3.3%C SDS–PAGE separating gel (1+18+18 mm), 
revealed by Sypro Ruby staining and visualized using a 
Typhoon 9200 laser scanner (GE Healthcare). Proteins 
were excised from the gel using Investigator ProPic spot 
picker (Genomic Solutions) and transferred to small tubes 
(0.2 ml). Protein-containing gel pieces were destained 
with 50 ml of 0.1M ammonium bicarbonate (5 min at RT). 
After two washes with 50% acetonitrile/0.05M ammonium 
bicarbonate, gel plugs were shrunk by addition of 100% 
acetonitrile. The dried gel pieces were re-swollen with 
4.5 ng/ml trypsin in 50mM ammonium bicarbonate and 
digested overnight at 378C. Peptides were concentrated 
with ZipTipmC18 pipette tips (Millipore). Coelution 
was performed directly onto a MALDI target with 1 ml 
of a-cyano-4-hydroxycinnamic acid matrix (5 mg/ml in 
50% acetonitrile, 0.1% TFA). Proteins were identified by 
Matrix Assisted Laser-Desorption Ionization (MALDI)-
MS and MALDI-MS/MS (4700 Proteomics Analyzer; 
Applied Biosystems). Data were acquired in positive 
MS reflector mode. Five peptides (ABI4700 Calibration 
Mixture; Applied Biosystems) were used as calibration 
standards. Mass spectra were obtained from each sample 
by 30 sub-spectra accumulation (50 laser shots each) in a 
750 to 4000. mass range. Five signal-to-noise best peaks 
of each spectrum were selected for MS/MS analysis. For 
MS/MS spectra, the collision energy was 1 keV and the 
collision gas was air. The interpretation of both the MS and 
MS/MS data was carried out by using the GPS Explorer 
software (Version 1.1, Applied Biosystems), which acts as 
an interface between the Oracle database containing raw 
spectra and a local copy of the MASCOT search engine 
(Version 1.8). Peptide mass fingerprints obtained from MS 
analysis were used for protein identification in the NCBI 
non redundant database. All peptides mass values were 
considered monoisotopic and mass tolerance was set at 50 
p.p.m. One missed cleavage site was allowed, cysteines 
were considered carboamidomethylated, methionine 
was 0assumed to be partially oxidized and serine, 
threonine and tyrosine partially phosphorylated. Mascot 
(Matrix Science) scores >61 were considered significant 
(P<0.005). For MS/MS analysis, all peaks with a signal-
to-noise ratio >5 were searched against the NCBI database 
using the same modifications as the MS database, with a 
fragment tolerance <0.3 Da.
Cell lines
Human breast cancer cell lines MCF-7 and SKB-R3, 
human colorectal carcinoma cell lines HCT-116 and SW-
480, human osteosarcoma with osteoblastic properties 
cells Saos-2, human primary fibroblasts (HF), and human 
cervical adenocarcinoma HeLa cells were all cultured in 
Dulbecco's modified Eagle's medium (DMEM, Gibco 
BRL) supplemented with 10% fetal calf serum and 
antibiotics in a humidified 5% CO2 atmosphere.
Total lysates extraction
Cells, harvested in cold phosphate-buffered saline, 
were extracted for 30 min at 4°C in lysis buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40) containing 
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1 mM DTT, protease inhibitor cocktail (Roche) and 
phosphatase inhibitors (50 mM NaF, 0.2 mM Na3VO4). 
After centrifugation, supernatants were collected as 
the total protein extract and stored at -80°C. Protein 
concentrations were measured using the Bradford-type 
protein assay (Bio-Rad).
Lamins solubilization
Cells were resuspended in hypotonic buffer 
(10 mM Hepes pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
0.5 % NP-40, 0.5 mM DTT, and protease inhibitors) and 
nuclei separated by centrifugation. Nuclei were then 
incubated 30 min in moderate-salt buffer buffer (300 
mM KCl, 2% Triton X-100, 10% sucrose, 20 mM MES-
KOH pH 6.0, 2 mM EDTA, 1 mM DTT) and centrifuged 
(3, 300g, 15 min, 4°C) to obtain a lamin-enriched pellet. 
This pellet was incubated on ice 30 min in high pH/high 
detergent buffer (300 mM KCl, 2% Triton X-100, 20 mM 
Tris-HCl pH 9.0, 2 mM EDTA, 1 mM DTT) followed by 
centrifugation (6, 000g, 20 min) to yield a supernatant 
of solubilized lamins (soluble lamins) and an insoluble 
pellet.
Chromatin extraction
Cells were lysed by mechanical homogenization 
in isotonic- sucrose based buffer (15 mM Tris-HCl pH 
7.5, 15 mM NaCl, 60 mM KCl, 5 mM MgCl2, 1 mM 
CaCl2, 250 mM Sucrose, 0.3 % NP-40, and protease 
inhibitors) followed by centrifugation (5 min, 1,300 g, 
4°C). The pellet, containing the nuclei, was resuspended 
and lysed in lysis buffer (20 mM Hepes pH 7.9, 1.5 mM 
MgCl2, 150 mM KOAc, 3 mM EDTA, 10% glycerol, 1 
mM DTT, 0.1% Nonidet P-40 and protease inhibitors) 
and centrifuged (5 min, 1,700 g, 4°C). The supernatant 
corresponds to the nucleoplasmic fraction and the pellet 
to the chromatin fraction.
Euchromatin isolation
Chromatin fraction, obtained as described above, 
was digested im MNase buffer (20 mM Tris pH 7.5, 15 
mM NaCl, 1 mM CaCl2) with Micrococcal nuclease to 
a final concentration of 1.2 units/mL for 5 minutes, and 
the reaction was quenched by 1 mM EGTA on ice for 10 
minutes. The sample was centrifuged at 1,000× g for 5 
minutes at 4°C to generate the supernatant, corresponding 
to the euchromatin fraction. The insoluble chromatin pellet 
was resuspended in 15 mM Tris, pH = 7.5, 0.5% SDS. 
Extraction of DNA
DNA was isolated from chromatin samples by 
extraction with an equal volume of phenol/chloroform 
(1:1), extraction with an equal volume of chloroform, 
ethanol-precipitated and then resuspended in water and 
loaded onto a 2% agarose gel.
Immunoprecipitation and immunoblotting
For immunoprecipitation experiments, lysates 
were clarified and immunoprecipitated at 4°C overnight 
in lysis buffer by adding protein G-agarose after 2 h of 
incubation with 2 μg of antibody. Proteins were resolved 
by SDS-PAGE and electro transferred to nitrocellulose. 
Each membrane was blocked with 5% non-fat dry milk 
in Tris buffered saline-Tween-20 (TBST) for 1 h at room 
temperature and subsequently incubated with primary 
antibody for 16 h at 4°C. The following antibodies were 
used: anti-NF-YA polyclonal (Santa Cruz), anti NF-YA 
monoclonal (Santa Cruz) and anti-lamin A (Santa Cruz) 
and anti-lamin A/C (Santa Cruz), anti-β actin (sigma-
aldrich). Immunoreactivity was detected by sequential 
incubation with HRP-conjugated secondary antibody.
For tissue total exstract preparation, after tissue 
dissection, the organs were immediately frozen on dry 
ice. Bone marrow was flushed out from the femur and 
tibia, as previously described [17]. Tissue extracts were 
prepared by homogenization in a 100 mM KPO4 lysis 
buffer (pH 7.8) containing 1 mM dithiothreitol, 4 mM 
ethylene glycol tetraacetic acid, 4 mM EDTA, and 0.7 mM 
phenylmethylsulfonyl fluoride.
Double immunofluorescence labeling and 
confocal microscopy analysis
Cells were fixed with 2% formaldehyde, permeated 
with 0,05% Triton X-100, blocked 1h with 5% BSA, and 
subjected to staining using anti-lamin A (Santa Cruz), 
anti-NF-YA monoclonal (Santa Cruz), Cy3-conjugated 
donkey anti-mouse and Cy2-conjugated donkey anti-
rabbit (Jackson Immuno Research Laboratories). 
Slides were analyzed within 24 h. As control, single 
immunofluorescence labeling for each antibody, and 
immunofluorescence labeling without primary antibody 
was performed (data not shown). All experiments were 
performed several times with similar results. Images 
were recorded by using a Zeiss LSM 510 Meta confocal 
laser scanning microscope equipped with a 20X and 
60X/1.23 NA oil immersion objective. As laser (488 and 
514 nm), and HeNe laser (543 nm) were used to excite the 
fluorophores. The LSM 510 R. 3.2 META (Zeiss) image 
analysis software was used.
Plasmids and transfections
Plasmids used in transfections were as follows: 
NF-YA and empty vector [1], wt cyclin B2 promoter (B2-
Luci) and mut cyclin B2 promoter (mutant Y1, 2m-luci) 
constructs [4], pMXIH-V5 and PMXIH-lamin A res [48], 
pcDNA6.2-GW and EmGFP-miR-LMNA (Invitrogen).
Cells were transfected with Lipofectamine LTX and 
Plus reagent (Invitrogen) following the manufacturer's 
instructions.
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Stably transfected cells were selected for by 
culturing the cells in the presence of blasticidin at10 μg/
mL (Invitrogen). The transfected cells were screened 
using western blotting and real-time RT-PCR assays 
to determine the levels of lamin A expression and the 
miRNA expression was monitored by checking the 
simultaneous coexpression of the EmGFP reporter 
gene by fluorescence microscopy. For reporter assay 
luciferase activity was measured using the dual luciferase 
assay system (Promega) according to the instructions 
of the manufacturers. All transfections were done as 
cotransfections with a CMV-driven plasmid expressing 
Renilla luciferase as internal control to standardize 
transfection efficiencies.
ChIP assay
1% formaldehyde was added directly to the cells and 
incubated at 22 °C for 10 min. The reaction was stopped 
adding 0.125 m glycine. Then, the cells were rinsed with 
cold 1× PBS, incubated with 0.2× trypsin-EDTA in 1× 
PBS, and scraped. cells were centrifuged, washed in cold 
1× PBS plus 0.5 mm PMSF and resuspended in lysis 
buffer (5 mm piperazine N, N bis zethone sulfonic acid 
(pH 8.85) mm KCl, 0.5% Nonidet P-40). Next, nuclei 
were solicited in the sonication buffer (0.1% SDS, 10 mm 
EDTA, 50 mm Tris-HCl (pH 8), 0.5% deoxycholic acid) 
for 10 min by using a microultrasonic cell disruptor. The 
chromatin was sheared to an average size of 500 base pairs, 
and immunoprecipitation was performed with protein 
G-agarose (KPL). The chromatin solution was precleared 
by adding protein G for 1 h at 4 °C and incubated at 
4 °C overnight with 4 μg of antibody or non-specific 
immunoglobulins (IgGs, Santa Cruz Biotechnology) 
as negative control. Input was collected from a control 
sample supernatant (not immunoprecipitated antibody). 
Immunoprecipitates were recovered by incubation for 
2 h at 4 °C with protein G-agarose precleared previously 
in immunoprecipitation buffer (1 μg/μl bovine serum 
albumin, 1 μg/μl salmon testis DNA, protease inhibitors, 
and PMSF). Reversal of formaldehyde cross-linking, 
RNase A, and proteinase K treatments were performed. 
DNA was phenol-extracted, ethanol-precipitated, and 
analyzed by PCR. DNA representing 0.005–0.01% 
of the total chromatin sample (input) or 1–10% of the 
immunoprecipitates was amplified using specific primers 
indicated in Table 1. The following antibodies were used: 
anti-Pol II phospho ser 3 (Upstate), anti Pol II phospho 
ser 5 (Upstate), anti-H3K14ac (Abcam), anti-H4K20me3 
(Abcam), anti-NF-YA polyclonal (Santa Cruz), anti NF-
YA monoclonal (Santa Cruz) and anti-lamin A (Santa 
Cruz) and anti-lamin A/C (Santa Cruz). PCR analysis 
was performed with HOT-MASTER Taq (Eppendorf). 
Quantitative PCR (qPCR) was performed using SYBR 
Green (Applied Biosystems) on an ABI Prism 7500 
apparatus (Applied Biosystems). Primers used are listed 
in Table 1.
RNA extraction and RT-PCR
Total RNA was extracted using the Trizol reagent 
(Gibco BRL) following the manufacturer's instructions. 
The first-strand cDNA was synthesized according to 
the instructions for the M-MLV RT kit (Invitrogen). 
Quantitative PCR (qPCR) was performed using SYBR 
Green (Applied Biosystems) on an ABI Prism 7500 
apparatus (Applied Biosystems). mRNA expression was 
normalized for β-actin levels. Primers used are listed in 
Table 2. Relative mRNA expression was calculated using 
the comparative Ct method (2−ΔΔCt).
Retroviral infection
Phoenix-ampho cells (American Type Culture 
Collection) were transfected with pMXIH-V5 or 
pMXIH-V5 Lamin A. The supernatant medium 
containing the emerging retrovirus was collected 48 
and 72 h after transfection. The supernatants were 
pooled and the retroviral particles were concentrated by 
ultracentrifugation at 22.000 rpm for 2 h, resuspended 
in cold PBS and stored at -80°C. The viral titer was 
determined infecting NIH3T3 murine fibroblasts at 
different serial dilutions. The retroviral vectors were 
injected into the tail vein in adult mice with 5.25x10^2/
mouse.
In vivo BLI and experimental animals
MITO_Luc C57Bl/6j [49] were interbred with FVB 
mice to obtain FVB MITO-Luc mice were maintained in 
the heterozygous state. After genomic DNA extraction of 
tail biopsies, the positive founder animals were identified 
by PCR using the following primers specific for the 
transgene: oligonucleotide up: 5′-TGTAGACAAGGA
AACAACAAAGCCTGGTGGCC; and oligonucleotide 
down: 5′-GGCGTCTTCCATTTTACCAACAGTACCGG. 
Light emission was detected using the IVIS Lumina II 
CCD camera system and analyzed with the Living Image 
2.20 software package (Caliper Life Sciences). Mice were 
anesthetized and 150 mg/kg or 75 mg/kg of D-luciferin 
were injected IP. Ten minutes later, quantification of light 
emission was performed in photons/second and visualized 
in a pseudo-color scaling. Time exposure ranged from 1 to 
5 minutes depending on light intensity.
All animal studies were approved by the Institutional 
Animal Care of the Regina Elena National Cancer Institute 
and by the Government Committee of National Minister of 
Health and were conducted according with EU Directive 
2010/63/EU for any-animal experiments http://ec.europa.
eu/environment/chemicals/labanimals/legislation en.htm.
Oncotarget16www.impactjournals.com/oncotarget
Table 2: PCR primers for mRNA quantification
CDK1 FWD GCGGAATAATAAGCCGGGATC
CDK1 REV CCCTTATACACAACTCCATAGGT
CDC25C FWD TCCTGGAGAGAGACACTTCC
CDC25C REV CAACGTTTTGGGGTTCCTCC
CCNB1 FWD TGCAGAAGATGGAGCTGATC
CCNB1 REV GTGACTTCCCGACCCAGTAG
CCNB2 FWD GCACATGGCCAAGAATGTGGTG
CCNB2 REV TCAGTGGGGAGGCAAGGTCTT
DHFR FWD AAACTGCATCGTCGCTGTGTC
DHFR REV ACCCATAATCACCAGATTCTGT
LMNA FWD GGACAATCTGGTCACCCGC
LMNA REV TGGCAGGTCCCAGATTACATG
ACTIN FWD GGACTTCGAGCAAGAGATGG
ACTIN REV AGCACTGTGTTGGCGTACAG
Table 1: PCR primers for ChIP assay
CCNB2 FWD ACCGGCTGT TGTGACAATCA
CCNB2 REV GGCCAACACAAGATGCACTCT
DHFR FWD CTGGAGACCTAAGGGCAGCTT
DHFR REV TTGGTGGTCGAAGAGTTTTACTGA
CCNA2 FWD GCCCCAGCCAGTTTGTTTC
CCNA2 REV GGCGAGTGAAGGGTAAACCA
CDK1 FWD CGTAGCTGGGCTCTGATTGG
CDK1 REV CAAACTCACCGCGCTAAAGG
CCNB1 FWD GCCCTGGAAACGCATTCT C
CCNB1 REV CCTCCTTATTGGCCTGTTCGT
CDC25C FWD GCTGGTGGGCCAAACACT A
CDC25C REV TGTGCTTGCTCTGGAAATGG
TOPO 2A FWD TGGCCAGATTCCCTGTCAAT
TOPO2A REV AGGTTAGGGAGGCGGGACTA
PCNA FWD CACATATGCCCGGACTTGTTC
PCNA REV CAGGTCTCCCCGCCTCTT
CXCR4 FWD AGTGGTTTGACCTCCCCTTT
CXCR4 REV ACTTGCACCTGCCAGTCTTC
ITS18-1 FWD TCCATGTGGTCTCTCTGTCTGGACT
ITS18-1 REV GACGGGCCAGACTGTTGCAT
Tel-Adj FWD CCCCTTGCCTTGGGAGAA
Tel-Adj REV GAAAGCAAAAGCCCCTCTGA
RPLP0 FWD GCGCCCATCTAACTAGCACA
RPLP0 REV TCGCGACCCTACTTAAAGGC
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